Claims for Patent: 9,920,324

Summary for Patent: 9,920,324

Title:	Polycistronic expression system for bacteria
Abstract:	The invention relates to polycistronic expression in gram-positive bacterium and in particular concerns polycistronic expression units comprising one or more gene endogenous to the gram-positive bacterium transcriptionally coupled to one or more genes exogenous to the bacterium.
Inventor(s):	Vanden-Broucke; Klaas (De Pinte, BE), Van Huynegem; Karolien (Asper, BE), Steidler; Lothar (Lokeren, BE)
Assignee:	INTREXON ACTOBIOTICS NV (Zwijnaarde, BE)
Application Number:	14/122,545
Patent Claims:	1. A pharmaceutical composition comprising a gram-positive bacterium comprising a polycistronic expression unit, wherein said polycistronic expression unit comprises a functional endogenous gene and one or more exogenous genes encoding a therapeutic polypeptide, wherein said endogenous gene and said one or more exogenous genes are transcriptionally controlled by a promoter endogenous to said gram-positive bacterium, wherein said promoter (i) is a ribosomal gene promoter or a glycolysis gene promoter, (ii) is the native promoter of said endogenous gene, and (iii) said promoter and said endogenous gene are located in their native chromosomal locus in the gram-positive bacterium, and wherein said endogenous gene is transcriptionally coupled to said one or more exogenous genes by chromosomal integration of said one or more exogenous genes into said locus. 2. The pharmaceutical composition of claim 1, wherein said promoter is selected from the group consisting of the promoters of eno, usp45, gap, pyk, rpmB and rplS of said gram-positive bacterium. 3. The pharmaceutical composition of claim 2, wherein said one or more exogenous genes is transcriptionally coupled to the 3' end of said endogenous gene. 4. The pharmaceutical composition of claim 3, wherein said one or more exogenous genes is the most 3' gene of said polycistronic expression unit. 5. The pharmaceutical composition of claim 1, wherein said endogenous gene and said one or more exogenous genes are transcriptionally coupled by intergenic region or regions active in said gram-positive bacterium. 6. The pharmaceutical composition of claim 5, wherein said intergenic region or regions is endogenous to said gram-positive bacterium. 7. The pharmaceutical composition of claim 5, wherein said intergenic region is selected from the group consisting of intergenic regions preceding rplW, rplP, rpmD, rplB, rpsG, rpsE, rplN, rplM, rplE, and rplF. 8. The pharmaceutical of claim 1, wherein said therapeutic polypeptide is present in a therapeutically effective amount. 9. The pharmaceutical composition of claim 1, wherein said therapeutic polypeptide has a preventive effect in a subject. 10. The pharmaceutical composition of claim 1, wherein said polypeptide is an antigen for inducing immunity or immunotolerance, a non-vaccinogenic therapeutically active polypeptide, or an antibody or a functional fragment thereof. 11. The pharmaceutical composition of claim 10, comprising a functional fragment of an antibody, wherein said functional fragment is an Fab fragment. 12. The pharmaceutical composition of claim 1, wherein said one or more exogenous genes are 3' of said endogenous gene in said locus. 13. The pharmaceutical composition of claim 1, wherein one of said one or more exogenous genes encodes a light chain (V.sub.L) of an antibody or a functional fragment thereof, and another of said one or more exogenous genes encodes a heavy chain (V.sub.H) of said antibody or a functional fragment thereof. 14. The pharmaceutical composition of claim 13, wherein said functional fragment is an Fab fragment. 15. The pharmaceutical composition of claim 13, wherein said exogenous gene encoding V.sub.L or functional fragment thereof is transcriptionally coupled to the 3' end of said exogenous gene encoding V.sub.H or functional fragment thereof. 16. The pharmaceutical composition of claim 1, wherein said gram-positive bacterium is a lactic acid bacterium or a Bifidobacterium. 17. The pharmaceutical composition of claim 16, wherein said lactic acid bacterium is a Lactococcus, a Lactobacillus, or an Enterococcus bacterium. 18. The pharmaceutical composition of claim 17, wherein said lactic acid bacterium is Lactococcus lactis or Enterococcus faecium. 19. The pharmaceutical composition of claim 1, further comprising a pharmaceutically acceptable carrier. 20. A method of delivering a therapeutic polypeptide to a human or animal subject comprising administering to said human or animal subject the pharmaceutical composition of claim 1, whereby said administration is effective to deliver said therapeutic polypeptide. 21. The pharmaceutical composition of claim 1, wherein said endogenous gene is a full length endogenous gene. 22. The pharmaceutical composition of claim 1, wherein said promoter is gapB, and wherein said gapB promoter is coupled to a gene encoding Human Trefoil Factor 1 (hTFF1) by an intergenic region comprising rpmD. 23. The pharmaceutical composition of claim 1, wherein said promoter is usp45, and wherein said usp45 promoter is coupled to a gene encoding Human pro-insulin (ins) by an intergenic region comprising rpmD. 24. The pharmaceutical composition of claim 1, wherein said promoter is enoA, and wherein said enoA promoter is coupled to a gene encoding Human pro-insulin (ins) by an intergenic region comprising rpmD. 25. The pharmaceutical composition of claim 10, wherein said polypeptide is a human pro-insulin, a human trefoil factor 1 (hTFF1), a human interleukin-10 (hIL-10), a human interleukin-27 (hIL-27), a cA2 anti-hTNF Fab or a CDP870 anti-TNF Fab. 26. The pharmaceutical composition of claim 2, wherein said one or more exogenous genes are transcriptionally coupled by intergenic region or regions active in said gram-positive bacterium. 27. The pharmaceutical composition of claim 26, wherein said intergenic region is selected from the group consisting of intergenic regions preceding rplW, rplP, rpmD, rplB, rpsG, rpsE, rplN, rplM, rplE, and rplF. 28. The pharmaceutical composition of claim 1, wherein the therapeutic polypeptide is selected from the group consisting of: a cytokine, a growth factor, and a wound healing factor. 29. The pharmaceutical composition of claim 10, wherein the antibody is selected from the group consisting of: a chimeric antibody, a dAb, a bispecific antibody, a trispecific antibody, a multispecific antibody, a bivalent antibody, a multivalent antibody, a nanobody, an Fab', an F(ab').sub.2, an scFv, an Fv, an Fd, a diabody, a triabody, a single chain antibody, and a single variable domain. 30. The pharmaceutical composition of claim 1, wherein the therapeutic polypeptide is selected from the group consisting of: IL-Ira, IL-10, IL-27, a trefoil peptide, an auto-antigen, an allergen, a gluten allergen, a brain derived neurotropic factor, a ciliary neurotropic factor, IL-1, a colony stimulating factor, interferon-.omega., transforming growth factor f3, insulin, a tissue plasminogen activator, a cytokine antagonist, a clotting factor, a hepatocyte growth factor, interferon .alpha., alpha antitrypsin.

Details for Patent 9,920,324

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	10/28/1982		2031-06-01
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	12/29/2015		2031-06-01
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	08/06/1998		2031-06-01
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	03/31/1994		2031-06-01
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	05/25/2018		2031-06-01
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	06/25/1991		2031-06-01